Business
Kezar Reports Third Quarter Financial Results and Provides Business Update
Target enrollment met in the MISSION Phase 2 trial evaluating KZR-616 for lupus nephritis First patient dosed in Phase 1 trial of KZR-261 for the treatment
About this update from Kezar Life Sciences, Inc.
[{"type":"text","content":"\n\nTarget enrollment met in the MISSION Phase 2 trial evaluating KZR-616 for lupus nephritis\n\n\nFirst patient dosed in Phase 1 trial of KZR-261 for the treatment of advanced solid tumor malignancies\n\n\nCompany to host virtual Investor and Analyst Day on Monday, November 15, 2021, at 4:30 p.m. ET to discuss KZR-616, including MISSION interim results, and KZR-261\n\n\nNew credit facility provides up to $50 million of available funding\n\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nKezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2021 and provided a business update.\n\n“Excellent progress continues across our programs, as we reached target enrollment in both of our Phase 2 trials with KZR-616 and announced our first patient dosed with KZR-261. Achieving full enrollment in our MISSION and PRESIDIO studies is an important milestone for KZR-616 as a potentially differentiated treatment option for patients suffering from lupus nephritis, dermatomyositis and polymyositis. We look forward to sharing interim results from MISSION at our upcoming event this month, with topline results from both studies expected in the second quarter of 2022,” said John Fowler, Kezar’s Co-founder and Chief Executive Officer.\n\nClinical Highlights & Updates\n\nKZR-616: Selective Immunoproteasome Inhibitor\n\nMISSION – Phase 2 clinical trial in patients with lupus nephritis (LN) (NCT03393013)\n\n\nKezar’s upcoming Investor and Analyst Day, scheduled for Monday, November 15, 2021, at 4:30 p.m. ET/1:30 p.m. PT, will include a presentation featuring interim MISSION data, as well as a presentation from Samir V. Parikh, MD, Associate Professor of Medicine, Nephrology, The Ohio State University Wexner Medical Center.\n\n\n\nThe MISSION Phase 2 open-label trial in patients with active, proliferative LN has reached target enrollment of 20 subjects. The primary efficacy endpoint for the trial is the number of patients with a 50% reduction in urine protein/creatine ratio (UPCR) after 24 weeks of treatment when compared to baseline.\n\n\n\nKezar expects to report topline data in the second quarter of 2022.\n\n\nPRESIDIO – Phase 2 clinical trial in patients wi...